Literature DB >> 8508816

Changes in circulating immune complexes during the Jarisch Herxheimer reaction in secondary syphilis.

C Loveday1, J S Bingham.   

Abstract

A cohort of 16 patients with early secondary syphilis were recruited to investigate the role of circulating immune complexes in the pathogenesis of the Jarisch Herxheimer reaction. Eleven of 16 patients had a reaction (68.75%) following initial therapy, characterised by rash potentiation, pyrexia, cardiovascular changes and a number of less specific symptoms. Circulating immune complexes were measured by a standard polyethylene glycol precipitation method and a new sensitive conglutinin binding assay that measured the proportion of IgG, IgM and IgA in complexes, in the first 8 hours after initial therapy. In the latter assay, resting levels of IgG (range 46-700 micrograms/ml) and IgM (range 100-410 micrograms/ml) containing complexes were raised in all patients prior to treatment, but levels were not predictive of those who subsequently had a Jarisch Herxheimer reaction. All patients having a reaction demonstrated a mean fourfold or greater rise in IgG (mean rise 712 micrograms/ml; range 180-1506 micrograms/ml) and IgM (mean rise 804 micrograms/ml; range 200-1120 micrograms/ml) containing complexes between two and eight hours after initial therapy. No such effect was seen in the five patients having no reaction or in a control subject. All these results were confirmed using the polyethylene glycol precipitation method for complex detection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8508816     DOI: 10.1007/BF01967109

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  The febrile Herxheimer reaction in early infectious and latent syphilis treated with penicillin.

Authors:  T PUTKONEN; K REHTIJARVI
Journal:  Acta Derm Venereol       Date:  1950       Impact factor: 4.437

2.  Pathogenesis of the Jarisch-Herxheimer reaction; a review of clinical and experimental observations.

Authors:  A HEYMAN; W H SHELDON; L D EVANS
Journal:  Br J Vener Dis       Date:  1952-06

3.  Biological effects of bacterial endotoxins in man.

Authors:  S M Wolff
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

4.  Physiologic changes during the Jarisch-Herxheimer reaction in early syphilis. A comparison with louse-borne relapsing fever.

Authors:  D A Warrell; P L Perine; A D Bryceson; E H Parry; H M Pope
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

5.  Circulating immune complexes in syphilis.

Authors:  J Sølling; K Sølling; K U Jakobsen; E From
Journal:  Acta Derm Venereol       Date:  1978       Impact factor: 4.437

6.  Changes in intravascular kininogen during the Jarisch-Herxheimer reaction in secondary syphilis.

Authors:  C Loveday; J S Bingham
Journal:  Br J Vener Dis       Date:  1982-12

7.  Precipitable immune complexes in healthy homosexual men, acquired immune deficiency syndrome and the related lymphadenopathy syndrome.

Authors:  H H Euler; P Kern; H Löffler; M Dietrich
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

8.  Human immunodeficiency viruses in patients attending a sexually transmitted disease clinic in London, 1982-7.

Authors:  C Loveday; L Pomeroy; I V Weller; J Quirk; A Hawkins; H Williams; A Smith; P Williams; R S Tedder; M W Adler
Journal:  BMJ       Date:  1989-02-18

9.  Circulating immune complexes in experimental syphilis: identification of treponemal antigens and specific antibodies to treponemal antigens in isolated complexes.

Authors:  R E Baughn; C B Adams; D M Musher
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

10.  Use of bovine conglutinin for the assay of immune complexes.

Authors:  R A Eisenberg; A N Theofilopoulos; F J Dixon
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

View more
  1 in total

Review 1.  Antibiotic-induced release of endotoxin. A therapeutic paradox.

Authors:  J C Hurley
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.